Rare diseases
Investigational molecules
Locations
Effingerstrasse 33, 3008
Research activity includes ER-positive/HER2-negative early breast cancer, operable invasive disease in premenopausal patients, and isolated locoregional recurrence of HR-positive, HER2-negative breast cancer. The portfolio also covers endocrine therapy combinations and post-recurrence treatment strategies.
Interest extends to treatment approaches that address residual risk after surgery and recurrence patterns in breast cancer.
ETOP IBCSG Partners Foundation runs clinical trials in conditions such as Non-small cell lung cancer, Non-small cell lung cancer stage III, Lung neoplasm malignant, Small cell lung cancer, among others.
Clinical trials run by this sponsor – those enrolling participants first.
France
AustriaAustria
ItalyFranceFrance
BelgiumAustriaFranceFranceIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
